Evidence map›Paper›PMID 33256058›Full record

ArticleMolecules (Basel, Switzerland)2020

Preparation and Biological Evaluation of [

Di Xiao, Xiaojiang Duan, Qianqian Gan, Xuran Zhang, Junbo Zhang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. EJNMMI radiopharmacy and chemistry · 2024
    Review
  5. A Preclinical Study of anPharmaceuticals (Basel, Switzerland) · 2022
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Di XiaoKey Laboratory of Radiopharmaceuticals of Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, China.
Xiaojiang DuanDepartment of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China.
Qianqian GanKey Laboratory of Radiopharmaceuticals of Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, China.
Xuran ZhangKey Laboratory of Radiopharmaceuticals of Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, China.
Junbo ZhangKey Laboratory of Radiopharmaceuticals of Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, China.
Beijing Normal University · CNPeking University First Hospital · CN

Funding

National Natural Science Foundation of China 21771023, 22076013the project of Beijing Municipal Science and Technology Commission Z181100002218033
6 · The paper itself

Abstract

Prostate-specific membrane antigen (PSMA) is a well-established biological target that is overexpressed on the surface of prostate cancer lesions. Radionuclide-labeled small-molecule PSMA inhibitors have been shown to be promising PSMA-specific agents for the diagnosis and therapy of prostate cancer. In this study, a glutamate-urea-based PSMA-targeted ligand containing an isonitrile (CNGU) was synthesized and labeled with

Indexed as

Radioactive TracersRadiopharmaceuticalsAnimalsAntigens, SurfaceGlutamate Carboxypeptidase IIHumansMaleMiceMolecular ImagingMolecular StructureNitrilesOrganotechnetium CompoundsProstatic NeoplasmsTechnetiumTomography, Emission-Computed, Single-PhotonAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IINitrilesOrganotechnetium CompoundsRadioactive TracersRadiopharmaceuticalsTechnetium99mTcisonitrileprostate cancerPSMASPECT imaging

Identifiers

PMID33256058
PMCPMC7730407
OpenAlexW3109591766

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.